Shares of Quidel QDEL fell 1.5% in after-market trading after the company reported Q3 results.
Quarterly Results
Earnings per share rose 725.71% over the past year to $5.78, which beat the estimate of $4.75.
Revenue of $476,058,000 up by 276.35% year over year, which beat the estimate of $450,390,000.
Outlook
Earnings guidance hasn't been issued by the company for now.
Quidel hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Oct 29, 2020
Time: 05:00 PM
ET Webcast URL: https://event.on24.com/wcc/r/2625296/E75E2243C47118925001E5956E2A2D04
Technicals
52-week high: $306.72
52-week low: $55.42
Price action over last quarter: down 6.89%
Company Description
Quidel Corp is engaged in the development, manufacturing, and marketing of rapid diagnostic testing solutions. It is separated into four product categories: Rapid immunoassays, Cardiac immunoassays, Specialized diagnostic solutions and Molecular diagnostic solutions. Rapid immunoassay and Cardiac immunoassay tests for use in physician offices, hospital laboratories and emergency departments, retail clinics, eye health settings, pharmacies and other urgent care sites, Specialized diagnostic solutions, including direct fluorescent assays and culture-based tests, and Molecular diagnostic tests across a number of hospitals, moderately complex physician offices, laboratories and other segments. The company generates a majority of its revenue from the rapid immunoassays.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.